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Abstract
The antidepressant fluoxetine has been under discussion because of its potential influence on cancer risk. It was found to
inhibit the development of carcinogen-induced preneoplastic lesions in colon tissue, but the mechanisms of action are not
well understood. Therefore, we investigated anti-proliferative effects, and used HT29 colon tumor cells in vitro, as well as
C57BL/6 mice exposed to intra-rectal treatment with the carcinogen N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) as
models. Fluoxetine increased the percentage of HT29 cells in the G0/G1 phase of cell-cycle, and the expression of p27
protein. This was not related to an induction of apoptosis, reactive oxygen species or DNA damage. In vivo, fluoxetine
reduced the development of MNNG-induced dysplasia and vascularization-related dysplasia in colon tissue, which was
analyzed by histopathological techniques. An anti-proliferative potential of fluoxetine was observed in epithelial and
stromal areas. It was accompanied by a reduction of VEGF expression and of the number of cells with angiogenic potential,
such as CD133, CD34, and CD31-positive cell clusters. Taken together, our findings suggest that fluoxetine treatment targets
steps of early colon carcinogenesis. This confirms its protective potential, explaining at least partially the lower colon cancer
risk under antidepressant therapy.
Citation: Kannen V, Hintzsche H, Zanette DL, Silva WA Jr, Garcia SB, et al. (2012) Antiproliferative Effects of Fluoxetine on Colon Cancer Cells and in a Colonic
Carcinogen Mouse Model. PLoS ONE 7(11): e50043. doi:10.1371/journal.pone.0050043
Editor: Nikos K. Karamanos, University of Patras, Greece
Received May 30, 2012; Accepted October 15, 2012; Published November 27, 2012
Copyright:  2012 Kannen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors disclosed receipt of the following financial support for the research of this article: DAAD (Deutscher Akademischer Austausch Dienst),
CAPES (Coordenac¸a˜o de Aperfeic¸oamento de Pessoa de Nı´vel Superior), CNPQ (Conselho Nacional de Desenvolvimento Cientı´fico e Tecnolo´gico), and FAPESP
(Fundac¸a˜o de Amparo a` Pesquisa do Estado de Sa˜o Paulo). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: stopper@toxi.uni-wuerzburg.de
Introduction
Colon cancer is one of the major human malignancies
worldwide, and much effort has been applied to understand the
process of colon carcinogenesis, as well as the role of potential
treatments and co-therapeutical agents against it [1–3]. A growing
body of evidence suggests that the use of fluoxetine (FLX), an
antidepressant belonging to the selective serotonin reuptake
inhibitors (SSRIs), may be associated with a reduced colon cancer
risk [4–6]. However, controversial opinions have been published
[7–13] and an identification of the mechanisms of the activity of
FLX on colon cells would help in the clarification of this
controversy.
We recently found that FLX reduced the number of 1,2
dimethylhydrazine (DMH)-induced preneoplastic colonic lesions,
termed aberrant crypt foci (ACF) and exerted an early anti-
VEGF activity on stromal cells, decreasing microvessel numbers
within pericryptal colonic stroma (PCCS) [5]. Tumor stroma
constitutes 60–90% of the colon tumor mass [14], and PCCS
surrounding the cryptal bottom has been reported to initiate
certain steps in colon tumor development, such as increased
proliferation, microvessel formation, VEGF-synthesis, regulation
of self-renewal and differentiation of intestinal cells [15–18].
ACFs are considered a suitable experimental model for studying
early stages of colon cancer formation, mainly due to their close
resemblance with the development of cancer in rodents and
humans [17,19].
Although FLX is known to decrease colon cell proliferation
in vitro [20], and in vivo models [5,21], the mechanism of its
antiproliferative activity is not well understood. Here we investi-
gated whether antiproliferative effects of FLX treatment play a
role in the chemoprevention of dysplasia in colon tissue and what
the involved mechanisms are. For this purpose, we used a human
colon cancer cell line (HT29) for in vitro experiments and an in vivo
model for studying carcinogen-induced preneoplastic lesions. The
in vivo model consisted of C57BL/6 mice exposed to intra-rectal
treatment with the alkylating mutagen and carcinogen N-methyl-
N’-nitro-N-nitrosoguanidine (MNNG). MNNG has been reported
to induce ACFs [22] to higher degree than 1,2 dimethylhydrazine
(DMH), the carcinogen previously used in colon cancer models by
our group [5,17,23].
Our results show that the antiproliferative effects of FLX-
treatment were not induced by increased apoptosis or production
of reactive oxygen species (ROS) or DNA damage. Instead FLX
reduced ACF numbers, most likely by controlling the activity of
stromal cells related to microvessel development.
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Materials and Methods
Reagents
Fluoxetine, tempol, hydrogen peroxide (H2O2), dimethyl
sulfoxide (DMSO), bisbenzimide, DAPI (49,6-diamidino-2-pheny-
lindole), and MNNG were purchased from Sigma-Aldrich (Louis,
MO, USA). DMEM (4.5 g/L glucose) medium were purchased
from PAA Laboratories GmbH (Austria). Dihydroethidium (DHE)
was acquired from Merck Millipore (Germany). Dichlorofluor-
escein (DCFH-DA) and Annexin V apoptosis detection kit (FITC),
and Cytofix/Cytoperm kit were acquired from Becton Dickinson
(Germany).
Cell Culture
The HT29 human colon cancer cell line was obtained from the
American Type Culture Collection (Manassas, VA, USA) and
cultured under standard conditions and grown in DMEM (4.5 g/
L glucose) medium. It was supplemented with 10% FBS, 1% L-
glutamine, penicillin (100 units/mL) and 0.1 mg/ml streptomycin.
Cells were seeded into 6-well plates (Sarstedt Inc., USA), at an
initial concentration of 56105 cells/well, and left untreated for 20–
24 hours. Then cells were exposed to 1, 10 or 100 mM FLX for 30
minutes, 4 or 24 hours. H2O2 (100 or 200 mM) served as control
for oxidative effects and DNA damage. Cells were exposed to
H2O2 for 30 minutes.
Flow Cytometry for Oxidative Stress, Viability and
Apoptosis, and Cell-cycle Analysis
Analysis for reactive oxygen species (ROS) production was
carried out in accordance with our standard method by flow
cytometry and argon laser excitation [24]. Briefly, cells were
labeled for 10 minutes with DCFH-DA and, then analyzed with a
FL1 band pass filter (Becton Dickinson [BD] LSR ITM, Germany).
Superoxide was detected after staining cells for 30 minutes with
DHE (10 mM) in medium without serum. After harvesting, cells
were analyzed with a FL2 band pass filter [25]. A viability and
apoptosis assay was performed by an Annexin V/Propidium
iodide (PI) kit and analyzed with FL1 and FL2 band pass filters,
according to the manufacturer’s instructions. For cell cycle
analysis, HT29 cells were incubated with FLX (1 mM and
10 mM) or the solvent DMSO (1%). Subsequently, cells were
permeabilized (Cytofix/Cytoperm kit) and stained with bisbenzi-
mide for 30 min. Experiments were analyzed with ultraviolet (UV)
laser excitation and a FL5 band pass filter. 20,000 cells were
analyzed per sample and evaluated with BD CellQuest ProTM
software. Cell cycle phases were analyzed by ModFit LT TM
software (Verity Software House, USA). At least four independent
experiments were carried out.
Comet Assay
According to our previous description [24], an alkaline version
of the comet assay was performed. The analysis encompassed 100
randomly selected cells (50 per replicate slide) for each sample,
which were analyzed with a fluorescence microscope (Labophot 2,
Nikon, Germany) at 200-fold magnification using Komet 5 image-
analysis software (BFI Optilas, Germany). The percentage of DNA
in the tail (% Tail DNA) was used to quantify DNA migration. At
least four independent experiments were carried out.
Western Blot Analysis
It was performed as described in NuPAGE Technical Guide
(Invitrogen, USA). Briefly, protein extracts were run on NuPAGE
4–12% Bis-Tris Mini Gels (Invitrogen), and transferred to
membranes with iBlot Dry Blotting System (Invitrogen).The
membranes were incubated 4uC overnight with anti-p27
(D69C12, Cell Signaling, USA), and anti-GAPDH (9484, Abcam,
UK) antibodies. Secondary antibodies (goat anti-rabbit and goat
anti-mouse IgG HRP antibodies) were incubated 1 h at room
temperature. Bands of labeled-antibodies were detected by using
SuperSignal West Pico Chemiluminescent Substrate (Thermo
Scientific, USA). Films were scanned and intensity of bands
quantified with ImageJ software. Data from 4 independent
Figure 1. Influence of Fluoxetine (FLX) on reactive oxygen species (ROS) production, DNA-damage, cell vitality/apoptosis and cell-
cycle progression in HT29 cells. (A and B) ROS production analyzed by flow cytometry, after exposure to different FLX concentrations for 30 min
(A), and 4 h (B; *P,0.05 vs DMSO). Hydrogen peroxide (H2O2) was used as positive control and in both cases applied for 30 min; arbitrary units (a.u.).
(C and D) O2
2 production detected by DHE staining for 30 min (C; P.0.05 vs DMSO), and 4 h (D; P.0.05). (E and F) DNA-damage analyzed by comet
assay, after exposure to different FLX concentrations for 30 minutes (E), and 4 h, with % DNA content in tail representing DNA-damage (F; *P,0.05 vs
DMSO). Hydrogen peroxide (H2O2) was used as positive control and in both cases applied for 30 min. (G) Viability and apoptosis assay (Annexin V/PI)
performed by flow cytometry, after exposure to different FLX concentrations for 24 hours (*P,0.05 vs DMSO). (H) Distribution of cells in cell cycle
phases analyzed by flow cytometry. Given is the percentage of HT29 cells in G0/G1, S, and G2/M phases with and without FLX treatment for 24 h
(**P,0.01 vs DMSO). All figures show results from at least 4 independent experiments.
doi:10.1371/journal.pone.0050043.g001
Figure 2. Effect of Fluoxetine (FLX) on p27 protein levels.
Relative expression of p27 protein in HT29 cells as determined by
Western blot analysis (P.0.05 vs DMSO). A sample blot and the average
result of 4 independent experiments are shown.
doi:10.1371/journal.pone.0050043.g002
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Figure 3. Chemopreventive activity of fluoxetine in colon tissue. (A) Representative histological image of a severely dysplastic area (MNNG-
exposed mouse). The picture inset (enlarged from the boxed region) shows the characteristic severe dysplastic features; e.g., partial loss of cell
polarity, none goblet cells, presence of Paneth cells (blue arrow), and mitosis (white arrows). Pictures were taken at 200x magnification, scale bars
represent 20 mm. High-magnification images were taken at 1000x magnification. (B) Representative image of a moderate dysplasia (MNNG+FLX
treated mouse). The inset shows a compressed cryptal luminal opening, elongated nuclei (red arrow), a crowded and pseudostrafied area (sectioned
black line), but with a generally still preserved cell polarity, and a lower number of globet cells (yellow arrow). Magnifications are described above. (C)
Quantification of dysplastic lesions. Aberrant crypt foci index (ACF-i) shown as number of dysplastic lesions per mm2 (*P,0.05; MNNG without FLX,
n = 5; FLX+MNNG, n= 4). (D) Aberrant crypt index (AC-i) shown as number of dysplastic single crypts per mm2 (*P,0.05; MNNG without FLX, n = 5;
FLX+MNNG, n= 4). (E) Representative image of a dysplastic area (sectioned black line), and its relative vascularization spreading inside. The inset
(enlarged from the boxed region) shows two microvessels towards the inner region of the dysplastic area. The yellow arrow points to a microvessel
wall, and the red arrow to erythrocytes inside the microvessel walls. Pictures were taken at 400x magnification, and further details are described
above. (F) Relative dysplastic vascularization, shown as the number of microvessels per lesion (*P,0.05; MNNG without FLX, n = 5; FLX+MNNG, n= 4).
doi:10.1371/journal.pone.0050043.g003
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experiments are shown as ratios between values from targeted and
endogenous control proteins.
Mice and Treatment Protocol
Female C57BL/6 mice (5 weeks) were supplied by the Medical
School of Ribeirao Preto, University of Sao Paulo, Brazil. All
in vivo treatments were in agreement with the protocol approved
by the Animal Care and Use Committee (nu 068/2012) from the
Medical School, University of Sa˜o Paulo, and the guidance for
animal managing at a minimum acceptable number. Mice were
acclimated for 1 week before starting the experiment. C57BL/6
mice were exposed or not to the carcinogen MNNG and randomly
assigned to one of four groups, as control (CTRL) or MNNG-
treatment (four successive doses of MNNG [5 mg/ml; intrarectal
deposits of 100 ml; Sigma-Aldrich, Louis, MO, USA] twice a week
for 2 weeks), and FLX-treatment (30 mg/kg/day; intraperitoneal,
i.p.; Sigma-Aldrich, Louis, MO, USA) or MNNG+FLX-treat-
ment. Each group had five mice, and they were housed per plastic
cage at 2262uC with 55% humidity and 12 h light/dark cycle.
FLX-application was started after 2 weeks from the end of
MNNG-treatment, and continued for the next 4 weeks. All
animals had free access to chow and water during the experiment.
All mice were euthanized by CO2 exposure at week 8 of the
experiment. Individual autopsies were performed, and colon tissue
samples were longitudinally opened and fixed flat in 4% neutral
paraformaldehyde-buffer (24 h). Mice with fragmented tissue
sections were discarded from the analysis.
Histopathological Analysis
Colon tissue samples were sectioned and stained with H&E and
analyzed using light microscopy. A tissue overview was carried out
at 200x magnification in colonic samples, where dysplastic
aberrant crypt foci (ACF) with pathological features ranging from
mild to severe dysplasia were detected and counted [26].
Afterwards, a second analysis was carried out at 400x magnifica-
tion on each detected lesion for confirmation of dysplastic features
and counting the number of aberrant crypts (AC) and microvessels
(MV). The whole area of each analyzed section was determined
with a graduated lens (100x; Nikon, Japan), and its area (mm2) was
calculated as values (V)6 0.9801/121. Relative values for ACF-i
(index) and AC-i were calculated as their total number per mm2
[5,17]. The vascularization-related dysplasia was determined to be
ACF6MV/AC.
Immunohistochemistry (IHC) and Immunofluorescence
(IMF)
According to previous description [5,27], IHC and IMF
staining were performed on paraffin colonic sections (4 mm).
Primary antibodies were purchased from Novocastra (USA), Santa
Cruz Biotechnology (Germany), and Biocare Medical (USA).
Sections were incubated with anti-Ki67 (clone MMA at 1:100),
anti-PCNA (clone PC 10 at 1:100), anti-c-Myc (clone 9E11 at
1:100), anti-VEGF (clone A-20 at 1:100), anti-CD34 (clone
QBEnd/10 at 1:100), anti-CD31 (clone 1A10 at 1:100), and
anti-CD133 (clone N/A at 1:100) primary antibodies overnight.
The brown color was displayed by incubating sections with
Picture-MAX Polymer Kit (Invitrogen, USA). It showed in
positive reactions a brown precipitate at the nucleus for Ki67,
and PCNA, and in the cytoplasm and/or perinuclei area for c-Myc,
VEGF, CD133, CD34, and CD31.
Proliferation in colonic sections was analyzed with anti-Ki-67
and anti-PCNA antibodies in epithelial and PCCS areas. Markers
associated with vascularization (VEGF, CD133, CD34, and
CD31) were counted in PCCS areas. However, CD31 (or
PECAM-1; platelet endothelial adhesion molecule-1) was counted
as positive cell clusters (more than 3 positive cells), since CD31 is
mainly expressed on the surface of endothelial cells [28]. Ratios
from counting were determined between positively stained nuclei
and total unstained nuclei in epithelia, whereas ratios in PCCS
areas were calculated between positive cells (or CD31 clusters) and
the total number of counted areas. For positive cells per cluster of
CD31, the ratio was calculated between the number of labeled
cells and the total number of clusters.
Double-labeling was performed in fixed colon samples labeled
with mouse anti-human CD133 (1:100; Miltenyl Biotec, 715-090-
422; secondary anti-mouse FITC conjugated antibody, 1:400,
Dianova, 715-095-150), rabbit anti-mouse VEGF (1:100, Santa
Cruz, sc-152; secondary anti-rabitt Cy3 conjugated antibody,
1:400, Dianova, 111-165-144), rat anti-mouse CD34 (1:100,
Applied Biosystems, ab 8158; secondary anti-rat Texas Red
conjugated antibody, 1:400, GeneTex, GTX 26732), and rabbit
anti-mouse CD31 (1:100, Applied Biosystems, ab 28365; second-
ary anti-rabitt Cy3 conjugated antibody, 1:400, Dianova, 111-165-
144) antibodies. Nuclei were stained with DAPI. Images were
acquired with an Olympus BX51 microscopy equipped with a
Olympus DP71 camera and a CellSens Dimension software
(Olympus, Germany).
Statistical Analysis
Data were analyzed using the statistical program GraphPad
Prism 5.0 (Graph Pad Software Inc., San Diego, California, USA).
Two-way ANOVA (Bonferroni post hoc test) test was applied to
analyze data from annexin V/PI and cell-cycle assays, and in vivo
experiments, since it allows different endpoints to be analyzed
separately. Oxidative stress and DNA damage were analyzed by
One-way ANOVA (Bonferroni post hoc test) test. Preneoplastic
lesions (ACF-i, AC-i, and vascularization-related dysplasia) were
analyzed by Mann Whitney test. A probability of P,0.05 was
considered to be statistically significant. All values represent
means6standard deviations.
Results
FLX Effects on ROS Production, DNA Damage, Cell
Viability, Apoptosis, and Cell-cycle
To understand whether and how therapeutic and over-
therapeutic concentrations of FLX could play a role against colon
Figure 4. Antiproliferative activity of fluoxetine in colon tissue. (A) Proliferating cells detected by staining with anti-Ki67 antibody (MNNG-
treated mouse). (1) Red arrows show dark-brown positive cells migrating upward in the epithelial proliferative zone. (2) Stromal positive cells are
shown by a red arrow near to the cryptal-bottom. Pictures were taken as described above. (B) Proliferating cells (anti-Ki67 antibody; red arrows) in a
MNNG+FLX-treated mouse are shown at the cryptal bottom. Pictures were taken as described above. (C) Proliferation in epithelial areas shown by
labeling with anti-Ki67 antibody (***P,0.001; MNNG without FLX, n = 5; FLX+MNNG, n= 4). (D) Proliferation in PCCS areas by labeling with anti-Ki67
antibody (***P,0.001; MNNG without FLX, n = 5; FLX+MNNG, n= 4). (E) Proliferation in epithelial areas shown by labeling with anti-PCNA antibody
(**P,0.01; MNNG without FLX, n = 4; FLX+MNNG, n= 4). (F) Proliferation in PCCS areas shown by labeling with anti-PCNA antibody (**P,0.01; MNNG
without FLX, n = 4; FLX+MNNG, n= 4). (G) Expression of c-Myc in epithelia of colon tissue (***P,0.001; MNNG without FLX, n = 3; FLX+MNNG, n= 4).
(H) Expression of c-Myc in PCCS areas of colon tissue (***P,0.001; MNNG without FLX, n = 3; FLX+MNNG, n= 4).
doi:10.1371/journal.pone.0050043.g004
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Figure 5. Fluoxetine activity and angiogenic-related markers. (A) Representative images of colon sections labeled with anti-CD133 and anti-
VEGF antibodies, and nuclei stained with DAPI. White arrows indicate single-stained and double-stained positive cells into PCCS areas in colon
sections from (A1 to A3) MNNG without FLX treatment, and (A4 to A6) MNNG+FLX treatment groups. Pictures were taken with FITC (495–521 nm),
ultraviolet (358–461 nm), and Texas Red (595–605 nm) filters. All pictures were taken at 600x magnification, scale bars represent 20 mm. (B)
Representative images of single colon-stained sections with anti-VEGF antibody (positive cells are seen with dark-brown cytoplasm) from (B1) MNNG
without FLX treatment, and (B2) MNNG+FLX treatment groups. (B3) Relative number of cells expressing VEGF within PCCS areas (***p,0.001; MNNG
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cancer cell proliferation, human colon cancer HT29 cells were
analyzed for ROS production, DNA damage, viability, apoptosis,
and the distribution of cell-cycle phases in the culture. We found
that ROS production was increased 2.5-fold in HT29 cells by
100 mM FLX after 30 min treatment, but no significant increase
was observed with 1 and 10 mM FLX (Figure 1A). Further
experiments showed that ROS were about 2-fold less in HT29
cells exposed to 100 mM FLX after 4 h than after the 30 min
treatment (Figure 1B). With the more superoxide specific dye
DHE a similar pattern was observed (Figure 1C and 1D). A 2.8-
fold increase with 100 mM FLX (Figure 1C), but no increase with
1 mM and 10 mM FLX was found after 30 min and a 2-fold
enhancement was observed after 4 h (Figure 1D), again only with
100 mM FLX. Thus, the increase with 100 mM FLX was 1.4-fold
less after 4 h treatment than after 30 min. None of the FLX
concentrations induced significant DNA damage in HT29 cells
after 30 min or 4 h experiments (Figure 1E and F).
After 24 h, 100 mM FLX decreased cell viability significantly
and induced apoptosis, although 1 and 10 mM were unable to
elicit similar effects (Figure 1G). On the other hand, 10 mM FLX
caused a significant delay of cells in the G0/G1 cell-cycle phase
during a 24 h treatment (Figure 1G). When the cell cycle
progression related protein p27 was investigated, 10 mM FLX
caused a slight upregulation and a 1.3-fold increase was found
after 24 h treatment with 20 mM FLX (Fig. 2). Taken together, a
G0/G1 cell-cycle delay occurred at a therapeutical FLX concen-
tration, which was not caused by ROS production or induction of
DNA damage.
Potential of FLX Against the Formation of Preneoplastic
Lesions
Based on the findings shown above, a chemopreventive activity
against preneoplastic lesions in colon tissue was verified for FLX
treatment in carcinogen-exposed mice. Mice were first exposed to
MNNG, treated with FLX for 28 days, and preneoplastic lesions
were enumerated by histopathological analysis. We observed
severe MNNG-induced dysplasia (Figure 3A) in colonic sections,
without FLX, n = 3; FLX+MNNG, n= 4). All pictures were taken at 400x magnification, scale bars represent 50 mm. (C) Representative images of colon
sections labeled with anti-CD133 and anti-CD34 antibodies, and nuclei stained with DAPI. White arrows indicate single-stained and double-stained
positive cells into PCCS areas in colon sections from (C1 to C3) MNNG without FLX treatment, and (C4 to C6) MNNG+FLX treatment groups. Pictures
were taken as described above. (D) Representative images of single colon-stained sections with anti-CD34 antibody (positive cells are seen with dark-
brown cytoplasm) from (D1) MNNG without FLX treatment, and (D2) MNNG+FLX treatment groups. (D3) Relative number of CD34 positive cells in
PCCS areas (***p,0.001; MNNG without FLX, n = 4; FLX+MNNG, n= 4). All pictures were taken as described above.
doi:10.1371/journal.pone.0050043.g005
Figure 6. Fluoxetine activity and an angiogenic-related marker. (A) Representative images of colon sections labeled with anti-CD133 and
anti-CD31 antibodies, and nuclei stained with DAPI. White arrows indicate single-stained and double-stained positive cells into PCCS areas in colon
sections from (A1 to A3) MNNG without FLX treatment, and (A4 to A6) MNNG+FLX treatment groups. (A3 and A6) Double-stained positive cells are
shown by white arrows in microvessel-like structures nearby cryptal bottoms. Pictures were taken with FITC (495–521 nm), ultraviolet (358–461 nm),
and Texas Red (595–605 nm) filters. All pictures were taken at 600x magnification, scale bars represent 20 mm. (B) Representative images of single
colon-stained sections with anti-CD31 antibody (positive cells are seen with dark-brown cytoplasm) from (B1) MNNG without FLX treatment, and
(B2) MNNG+FLX treatment groups. Pictures were taken at 400x magnification, scale bars represent 50 mm. (B3) Relative number of CD31 positive cell
clusters detected per PCCS area (**p,0.01; MNNG without FLX, n = 4; FLX+MNNG, n= 4).
doi:10.1371/journal.pone.0050043.g006
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which was not observed to such a grade in samples from FLX-
treated animals (Figure 3B). Quantification of dysplastic lesions
(ACF) in MNNG and MNNG+FLX-treated mice showed that
FLX reduced dysplasia 5.39-fold (Figure 3C). FLX treatment
significantly reduced the total values of AC per mm2 7.94-fold
(Figure 3D). Microvessels were spread throughout PCCS towards
dysplastic areas (Figure 3E), and we found that FLX treatment
decreased the vascularization-related dysplasia 3.13-fold
(Figure 3F). Our data suggest that FLX acts in different colonic
areas, namely epithelia and stroma.
Activity of FLX on Proliferation in Epithelia and PCCS
Areas
Since we indentified chemopreventive effects under FLX-
treatment in colon tissue, the question was raised whether these
findings were related to antiproliferative activities in two different
colonic areas, namely epithelia and PCCS areas (Figure 4A.1 and
2). Labeled sections with anti-Ki67 antibody revealed that FLX
attenuated (Figure 4B) the MNNG-induced increase in prolifer-
ation, at epithelial and PCCS areas (Figure 4C and D). PCNA
staining also showed that FLX attenuated the MNNG-induced
proliferative activity at both colonic areas (Figure 4E and F).
Furthermore, a high c-Myc expression was found at both colonic
areas in MNNG-treated animals, in which FLX-treatment
prevented the increase of expression (Figure 4G and H). Thus,
our findings support the hypothesis that inhibition of proliferation
plays an important role in the chemopreventive effects of FLX
treatment.
Activity of FLX on Angiogenesis
Considering that angiogenesis takes place within PCCS, and
proliferation as well as stem cell markers might be related to that
[15–16,29–30], we investigated the potential connection between
these events under FLX treatment. CD133-positive cells express-
ing VEGF were found within PCCS in mice subjected either to
MNNG or MNNG+FLX treatments (Figure 4A). FLX treatment
decreased their relative number in the carcinogen-exposed group
compared to the MNNG group without FLX (MNNG, 3.7360.44
[n=4] vs MNNG+FLX, 1.9760.14 [n=4]; P,0.001). Stromal
cells expressing VEGF were also decreased in MNNG-exposed
animals treated with FLX expression (Figure 5B). Intriguingly,
CD133 positive cells expressing CD34 glycoprotein were only
found among MNNG treated mice (Figure 5C) while FLX
treatment significantly decreased the number of stromal CD34-
positive cells (Figure 5D). Further, the relative total number of
CD31-positive cells was enumerated within PCCS areas, and a
significant decrease was found in the MNNG-exposed group
under FLX treatment (MNNG, 3.560.87 [n=4] vs MNNG+FLX,
1.860.2 [n=4]; P,0.01). A comparison between CD34 and
CD31-positive cells showed a 1.2-fold increase in CD31-positive
cell values among MNNG-exposed mice.
Since CD31 is an angiogenesis-related marker [31] and was
enhanced under MNNG-treatment, double-staining was per-
formed to understand whether CD133 positive cells were
expressing CD31 glycoprotein. In the MNNG and MNNG+FLX
groups, CD133 positive cells expressed CD31 in microvessel-like
structures within PCCS areas (Figure 6B). Potential sites of
developing microvessels were detected enumerating CD31-positive
cell clusters within PCCS (Figure 6B.1 and B.2). CD31-positive
cell clusters were decreased significantly under FLX-treatment in
MNNG-exposed mice (Figure 6B.3). Therefore, these data lead to
the hypothesis that a reduction of microvessel formation might be
occurring due to the control of FLX upon the stromal cell
differentiation process.
Discussion
Therapeutical concentrations of FLX range from 10 to 30 mM
in the human brain [32]. This concentration (10 mM) delayed cell-
cycle progression independently of ROS production and DNA-
damage in human colon cancer cells in vitro. Similar findings of
FLX blocked cell cycle progression arresting breast tumors cells at
Go/G1 phase have been reported previously [33]. These authors
found among other evidence an accumulation of p27 and
developed a modeling-based hypothesis that FLX can disrupt
the assembly of cyclin dependent kinase subunit 1 (CKS1) with
ubiquitin ligase skp2, preventing ubiquitination and proteasomal
degradation of p27. We also detected a p27 upregulation, which is
consistent with the hypothesis of Krishnan et al. [33]. In another
report using HT29 cells, FLX was shown to inhibit ERK1/2
phosphorylation by hypophosphorylating c-Myc and CREB
proteins, which resulted in downregulation of cyclin D1 and A,
whilst cell-cycle check point genes were upregulated, reducing cell
proliferation [20].
Looking at our in vitro results and the chemopreventive activity
of FLX against MNNG-induced dysplasia through reduced
epithelial proliferation, it seems possible that FLX promotes these
effects by controlling cell-cycle progression in vivo. It is known that
cells mutated under MNNG exposure can acquire increased
cellular proliferation capacity through changes in oncogene and
miRNA expressions [34]. On the other hand, a delay in the G2/M
phase of the cell-cycle was reported in colon cancer cells exposed
to MNNG [35]. Furthermore, the carcinogenic activity of MNNG
has been related to high cell proliferation in colonic epithelia
[22,36–37], whereas a chemoprevention against the induced
dysplastic effects was related to a decrease in proliferation and
expression of oncogenes, such as c-Myc [36,38]. Hence, MNNG
alters cell-cycle progression through induction of mutations
leading to increased proliferative capacity. FLX was found to
reduce cryptal proliferation by influencing serotoninergic activity
[5] and to induce expression of tumor suppressors, namely p53,
p27, and p21 [20,33].
Since high proliferation plays an important role in angiogenesis
[29], we hypothesized that the reduction in stromal proliferation in
mice subjected to FLX treatment might played a key role in
decreasing the angiogenesis-related dysplasia. Our current findings
further support the hypothesis that the anti-angiogenic activity of
FLX might be related to the control of angiogenesis-related stem
cell markers in colon preneoplastic lesions. Our previous report
already showed that FLX reduced colonic microvessel density by
decreasing VEGF expression in preneoplastic lesions [5], and that
high stromal proliferation increased the number of CD133-
positive cells [17]. An intriguing possibility was indicated by the
discovery of a small subset of stromal spindle cells expressing
CD133 and CD34 in angiofibromas [39]. These authors suggested
an acquired potential of stromal cells to transit toward an
endothelial phenotype [39]. Further reports reinforced this
hypothesis, since endothelial progenitor cells lose the expression
of CD133 during their differentiation process into vascular cells,
while the expression of CD34 is increased [30,40–41]. This
process has also been related to high proliferation [29], which
might mean a downregulation in CD34 expression upon further
differentiation [42]. Intriguingly, vascular smooth muscle cells
increased the expression of CD31 during their differentiation
process, whereas a simultaneous decrease of CD133 and CD34
progenitor markers was observed [43]. In addition, CD31-positive
cells have been designated as a mature endothelial lineage
promoting microvessels [31]. All in all, angiogenesis is one of the
most important tissue reactions enhancing preneoplastic lesion
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formation and tumor growth [14,29,44], as well as a suitable target
for anti-cancer therapies [45–46].
In summary, our findings show that antiproliferative effects of
FLX upon colon cells were not dependent on ROS production or
DNA damage. Instead, the inhibition of the formation of
preneoplastic lesions seems to be achieved by blocking steps of
proliferation and angiogenesis-related events in colon tissue. These
findings provide new aspects in the understanding of the
chemopreventive activity of FLX treatment concerning colon
cancer risk.
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